Annovis Bio (NYSE:ANVS) is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for neurodegenerative and other age-related diseases. The company’s lead product candidate, ANVS401 (Posiphen), is designed to inhibit the aggregation of pathogenic proteins such as tau, amyloid-β and alpha-synuclein, with the goal of slowing or halting the progression of Alzheimer’s disease, Parkinson’s disease and related disorders. Annovis Bio applies a multi-target approach, leveraging mechanisms that address toxic protein accumulation, neuroinflammation and disrupted neuronal signaling.
In addition to its neurological pipeline, Annovis Bio is advancing programs targeting acute respiratory distress syndrome (ARDS) and chronic pulmonary conditions. These programs explore the company’s proprietary small-molecule platform, which has shown potential in preclinical models to modulate endosomal trafficking and inflammatory pathways in lung tissue. With a focus on diseases that have high unmet medical need and limited treatment options, Annovis Bio combines translational research with regulatory engagement to move its candidates through Phase 1 and Phase 2 clinical trials.
Founded in 2005 and headquartered in New York City, Annovis Bio operates research facilities both in the United States and in Israel. The company collaborates with leading academic institutions and contract research organizations to support its discovery, nonclinical and clinical development efforts. Throughout its history, Annovis Bio has secured patent protection for its core technology and established licensing agreements that underpin its multi-indication strategy.
Under the leadership of President and CEO Jonathan Caro, Ph.D., Annovis Bio has grown its management and scientific teams to include experts in neurology, pharmacology and biomanufacturing. The board of directors and advisory committees feature seasoned professionals with backgrounds in drug development, regulatory affairs and commercial strategy. Together, they aim to advance Annovis Bio’s pipeline toward regulatory milestones and, ultimately, potential new therapies for patients with neurodegenerative and pulmonary diseases.
